Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of E6130 in Healthy Adult Males
NCT03390647Phase 1Withdrawn
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Dec 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of E6130 in inflammatory bowel disease (IBD) (3 arms), sponsored by EA Pharma Co., Ltd. Primary endpoint: Treatment-Emergent Adverse Events. Planned start Dec 2017; status: withdrawn.
02
Drugs
E6130
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT03390647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03390647.